[Pubmed] Association of baseline acetylcholine receptor antibody levels with efgartigimod treatment efficacy for patient
Posté : 06 nov. 2025 12:00
J Neurol Sci. 2025 Oct 29;479:123745. doi: 10.1016/j.jns.2025.123745. Online ahead of print.
ABSTRACT
BACKGROUND: Efgartigimod is effective for many patients with acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (gMG). To help identify patients most likely to benefit from efgartigimod, we examined the correlation between baseline AChR antibody levels and clinical response.
METHODS: This retrospective observational study included 10 AChR antibody-positive MG patients receiving efgartigimod at a single center. Clinical responses were assessed by MG Activities of Daily Living (MG-ADL) scores before treatment as well as 15 and 29 days after treatment initiation.
RESULTS: Patients demonstrated clinical improvement by day 15 as indicated by improved total MG-ADL score (mean, 3.6; range, -1 to 9; p = 0.0055), and condition improved further by day 29 (mean, 5.2; range, 2-10; p = 0.0003). Serum AChR antibody levels at baseline were positively correlated with MG-ADL score improvement on day 29 (r = 0.6483, p = 0.0426).
CONCLUSIONS: Generalized MG patients with high baseline AChR antibody levels may exhibit a superior response to efgartigimod.
PMID:41197538 | DOI:10.1016/j.jns.2025.123745
Source: https://pubmed.ncbi.nlm.nih.gov/4119753 ... 22+67771e2